The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes.
Questions:
1. What are the current challenges in managing cases of generalized myasthenia gravis? (00:14)
2. What did the ADAPT trial aim to demonstrate in patients with generalized myasthenia gravis? (02:21)
3. What effect on patient quality of life has efgartigimod demonstrated? (04:16)
4. How will these findings translate into care strategies for generalized myasthenia gravis? (05:35)
The abstract titled ‘Efgartigimod improved quality-of-life in gMG: a randomised, double-blinded, placebo-controlled, phase 3 trial (ADAPT)’ (Abstract #EPR-097) was presented at the European Academy of Neurology Congress 2022, 25–28 June 2022.
Disclosures: Francesco Saccà has participated in advisory boards for Alexion, Almirall, Argenx, Avexis, Biogen, Forward Pharma, Lexeo Therapeutics, Merk, Novartis, Novatek, Roche, Sanofi and Takeda; and received honoraria from Alexion, Argenx, Biogen, Mylan, Novartis, Roche, Sanofi and Teva.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of EAN 2022.
Click here for more content on this topic.
